Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 6/20 | 0.47 |
| ▸ | ACE | P12821 | 3/20 | 0.47 |
| ▸ | CPA1 | P15085 | 3/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 5/20 | 0.44 |
| ▸ | MMP9 | P14780 | 4/20 | 0.44 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27534943 | 1.00 | POLB (0.50) | POLBMMEACECPA1ACE2 | |
| SCHEMBL7416059 | 0.86 | MME (0.45) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL7416053 | 0.86 | MME (0.45) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL7416066 | 0.83 | MME (0.47) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL7416062 | 0.83 | MME (0.47) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL27514797 | 0.82 | ACE (0.45) | POLBACEALDH1A1MAPTKMT2A | |
| SCHEMBL5573305 | 0.82 | ACE (0.45) | POLBACEALDH1A1MAPTKMT2A | |
| SCHEMBL27541181 | 0.81 | NPSR1 (0.48) | POLBMMEACEACE2ALDH1A1 | |
| SCHEMBL5850598 | 0.81 | NPSR1 (0.48) | POLBMMEACEACE2ALDH1A1 | |
| SCHEMBL16465226 | 0.80 | FPR2 (0.51) | MMEACECPA1ACE2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166580-B2 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2007-01-23 | — | — | US | claimed |
| US-20030166575-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN MA INC. | 2003-09-04 | — | — | US | claimed |
| EP-1001973-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-24 | — | — | EP | claimed |
| WO-1999006433-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | claimed |
| US-7166580-B2 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20030166575-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN MA INC. | 2003-09-04 | — | — | US | disclosed |
| US-6559127-B1 | Intercellular adhesion mediated by VLA-4 and other cell surface receptors is associated with a number of inflammatory responses | ATHENA NEUROSCIENCES, INC. | 2003-05-06 | — | — | US | disclosed |
| CN-1265669-A | Compounds that inhibit leukocyte adhesion mediated by VLA-4 | ELAND PHARMACEUTICALS CO (US) | 2000-09-06 | — | — | CN | disclosed |
| EP-1001973-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999006433-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166575-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, CD4 | POLB 3968/4885MME 1315/4885ACE 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.